20
Participants
Start Date
April 27, 2022
Primary Completion Date
November 30, 2024
Study Completion Date
March 31, 2026
Blood sampling in addition to the blood normally required for their clinical management
Patients will undergo blood sampling in addition to the blood normally required for their clinical management. The study aims to collect 50 blood samples (one to 4) from 20 patients undergoing treatment in the adjuvant or advanced (metastatic) setting, as per standard of care. The first blood sample (T1) will be carried out immediately before the treatment, the subsequent blood samples (T2-T4) will coincide with the periodic radiographic re-evaluations, typically at months 3 and 6 (M3 and M6, T2 and T3), and at progression/recurrence, if and when recorded.
Blood plasma and circulating tumor DNA (ctDNA)
Blood drawing by venepuncture (elbow) in K2EDTA vacutainers to obtain blood plasma.The patients will otherwise receive the most appropriate treatment for their condition. The following data will be collected and pseudo-anonymised: demographic data (age and gender), histopathology including primary and metastatic sites, BRAF status, medical imaging, previous therapies assigned if any
RECRUITING
"Regina Elena National Cancer Institute", Rome
Collaborators (1)
VTT Technical Research Centre, Finland
OTHER
Institute of Health Information and Statistics of the Czech Republic
OTHER_GOV
Universita degli Studi di Catania
OTHER
FINNADVANCE (FIN)
UNKNOWN
PDC Biotech GmbH
INDUSTRY
Regina Elena Cancer Institute
OTHER